cyclic heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-31. Anything still debated is marked as such rather than presented as settled.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
HMRC reverses the plan for its self-assessment helpline, announced the previous day, following criticism from the public and MPs. The Senedd approves Vaughan Gething as the next First Minister of Wales. The London Clinic, where the Princess of Wales underwent abdominal surgery, announces that "any breach" of patient confidentiality will be investigated after reports a member of staff tried to access her private records. 21 March The Bank of England leaves interest rates unchanged at 5.25%, for the fifth time in a row. A report published by the Parliamentary and Health Service Ombudsman recommends women born in the 1950s who were affected by the 2010 changes to the state pension age should receive compensation of between £1,000 and £2,900. 22 March Following media speculation about her health, it is revealed that the Princess of Wales has been diagnosed with cancer and is undergoing treatment. Wetherspoons reports an eightfold increase in pre-tax profits during the first six months of the 2023–24 financial year. 23 March – A report compiled by the Resolution Foundation indicates a rise in the number of people leaving work due to long-term health conditions, with the number of people inactive due to long-term health conditions rising from 2.1 million in 2019 to 2.8 million in October 2023, the longest sustained rise since 1994–1998 when records began. The UK is also the only country in the G7 not to return to pre-pandemic employment levels.
=== Pharmacokinetics === The oral activity of nandrolone has been studied. With oral administration of nandrolone in rodents, it had about one-tenth of the potency of subcutaneous injection of nandrolone. Nandrolone has very low affinity for human serum sex hormone-binding globulin (SHBG), about 5% of that of testosterone and 1% of that of DHT. It is metabolized by the enzyme 5α-reductase, among others. Nandrolone is less susceptible to metabolism by 5α-reductase and 17β-hydroxysteroid dehydrogenase than testosterone. This results in it being transformed less in so-called "androgenic" tissues like the skin, hair follicles, and prostate gland and in the kidneys, respectively. Metabolites of nandrolone include 5α-dihydronandrolone, 19-norandrosterone, and 19-noretiocholanolone, and these metabolites may be detected in urine. Single intramuscular injections of 100 mg nandrolone phenylpropionate or nandrolone decanoate have been found to produce an anabolic effect for 10 to 14 days and 20 to 25 days, respectively. Conversely, unesterified nandrolone has been used by intramuscular injection once daily.
==== Musculoskeletal and bone tissues ==== Musculoskeletal applications represent a commercially mature sector of tissue engineering, focusing on the repair of critical-sized bone defects, articular cartilage lesions, and volumetric muscle loss. For orthopedic bone regeneration, therapeutic approaches utilize osteoconductive and osteoinductive scaffolds composed of bioceramics (such as hydroxyapatite and beta-tricalcium phosphate), biodegradable polymers, or composite hydrogels. These matrices serve as physical frameworks that recruit endogenous mesenchymal stem cells (MSCs) and promote osteogenesis. A critical challenge in bone tissue engineering is achieving adequate neovascularization within the core of large scaffolds to prevent core necrosis before host capillary ingrowth occurs. Consequently, modern biomaterial designs often implement multi-scale porosity, integrating smaller voids for nutrient diffusion with macro-channels greater than 100 micrometers, to facilitate deep cellular infiltration, matrix mineralization, and functional host tissue integration.
Impact Factor is not a perfect tool to measure the quality of articles but there is nothing better and it has the advantage of already being in existence and is, therefore, a good technique for scientific evaluation. Experience has shown that in each specialty the best journals are those in which it is most difficult to have an article accepted, and these are the journals that have a high impact factor. Most of these journals existed long before the impact factor was devised. The use of impact factor as a measure of quality is widespread because it fits well with the opinion we have in each field of the best journals in our specialty....In conclusion, prestigious journals publish papers of high level. Therefore, their impact factor is high, and not the contrary. As impact factors are a journal-level metric, rather than an article- or individual-level metric, this use is controversial. Eugene Garfield, the inventor of the JIF agreed with Hoeffel, but warned about the "misuse in evaluating individuals" because there is "a wide variation [of citations] from article to article within a single journal". Despite this warning, the use of the JIF has evolved, playing a key role in the process of assessing individual researchers, their job applications and their funding proposals. In 2007, The Journal of Cell Biology noted that:
== Function == Prolactin cells are best known for their role in female reproduction, particularly in stimulating the growth of mammary tissue and promoting lactation (milk production). Beyond female reproduction and common to both sexes, the prolactin hormone released by prolactin cells contribute to other physiological processes such as the regulation of the immune system, the stress response, and mood. Prolactin binds to receptors located on alveolar epithelial cells, stimulating the synthesis of the milk components including lactose, casein, and lipids. Lactose is the carbohydrate of milk, and casein is the protein of milk. While a mother is nursing and receiving nipple stimulation, prolactin levels spike and milk production occurs. “Prolactin levels fall to non-pregnant levels after 1 to 2 weeks” when the mother is no longer nursing the child. Prolactin, therefore, can be considered a short-term positive feedback mechanism, as high levels of prolactin stimulate more prolactin secretion from the prolactin cells of the pituitary gland. During pregnancy, prolactin influences the body metabolically, increasing appetite, fat storage, and the transfer of glucose to the fetus. Prolactin regulates both bone and calcium homeostasis, acts to suppress ovulation, and stimulates secretion of oxytocin. In addition to the pituitary gland, prolactin is produced by T cells, B cells (lymphocytes of the immune system), and macrophages.
Sources: en.wikipedia.org
== Background == Pedro Cuatrecasas was born in Madrid, Spain on 27 September 1936. He completed his A.B. from Washington University in St. Louis in 1958. He completed his M.D. from Washington University School of Medicine in 1962. Cuatrecasas died in La Jolla, California on 19 March 2025, at the age of 88.
Internal coenzyme/cofactor photocatalyst External photocatalyst Certain common hydrogen atom transfer (HAT) cofactors (NADPH and Flavin) can operate as single electron transfer (SET) reagents. Although these species are capable of HAT without irradiation, their redox potentials are enhance by nearly 2.0 V upon visible light irradiation. When paired with their respective enzymes (typically ene-reductases) This phenomenon has been utilized by chemists to develop enantioselective reduction methodologies. For example medium sized lactams can be synthesized in the chiral environment of an ene-reductase through a reductive, baldwin favored, radical cyclization terminated by enantioselective HAT from NADPH. The second category of photoredox enabled biocatalytic reactions use an external photocatalyst (PC). Many types of PCs with a large range of redox potentials can be utilized, allowing for greater tunability of reactive compared to using a cofactor. Rose bengal, and external PC, was utilized in tandem with an oxidoreductase to enantioselectively deacylate medium sized alpha-acyl-ketones. Using an external PC has some downsides. For example, external PCs typically complicate reaction design because the PC may react with both the bound and unbound substrate. If a reaction occurs between the unbound substrate and the PC, enantioselectivity is lost and other side reactions may occur.
==== Lieutenant of the Royal Victorian Order (LVO) ==== Hamish Blair, Senior Executive Officer, Scottish Office. Captain Robert Neil Blair, Royal Navy, Private Secretary to The Duke of York and to Princess Alexandra, the Honourable Lady Ogilvy. Laurence Albert Brown. For services to the Royal Collection. Donald Reeve Buttress, Surveyor of the Fabric, Westminster Abbey. Bernard Joseph Frahm, . For services to the Crown on Royal Visits to New Zealand. Commander Thomas Dixon Laidlaw, , Metropolitan Police. Leonora Mary, The Countess of Lichfield, Extra Lady in Waiting to The Princess Royal. Allan Arthur Percival, lately Press Secretary to The Prince of Wales. Alexander Hay Sutherland, Chief Publicity Officer, Scottish Office.
=== After independence === The BSAP's name remained unchanged by the Unilateral Declaration of Independence, although following the declaration of a republic by Ian Smith's government in 1970, the St Edward's Crown was removed from the BSAP's badge, and the appointment of Queen Elizabeth the Queen Mother as Honorary Commissioner was suspended. In place of St. Edward's Crown, the Zimbabwe Bird was displayed on cap badges.
Sources: en.wikipedia.org
==== Structured breast prosthesis ==== The fourth category of prosthetic-breast technology is the structured breast-prosthesis, which was approved for breast surgery by the Food and Drug Administration in the U.S. and by Health Canada in Canada in 2014. As a medical device, the structured prosthetic-breast incorporates the technologies of saline-solution and of silicone-gel to achieve anatomical function and aesthetic symmetry. Technologically, the internal structure of the breast prosthesis is composed of three, nested shells (made of silicone rubber) that support the upper half of the breast hemisphere; the two spaces between the three nested shells is filled with saline solution. To implant a structured breast prosthesis, the plastic surgeon emplaces the folded, empty prosthetic breast into the implant-socket, then fills the prosthetic breast with saline solution, and afterwards sutures shut the insertion incision.
Overall, without considering race, approximately 1.5% of infants born in the United States are carriers of at least one copy of the mutant (disease-causing) gene. In June 2026 it was reported that Daniel Cressy, an African American from Louisiana was cured from the disease after going through curative gene therapy.
(1908), chairman of Citigroup 1948–1952 Edmond Guggenheim (1908), mining executive, grandson of Meyer Guggenheim Ward Melville (1909), founder of the Melville Corporation that owned CVS Health, Marshalls, and Thom McAn shoes; helped the establishment of Stony Brook University and Stony Brook Village Center John Vernou Bouvier III* (1914), stockbroker and socialite, father of Jacqueline Kennedy Onassis, transferred to Yale College after two years Armand G. Erpf (1917), senior partner at Loeb, Rhoades & Co., chairman of the Crowell-Collier Publishing Company, financial architect of the New York magazine Alan H. Kempner (1917), stockbroker and publishing executive, son-in-law of banker Carl M. Loeb Lindsley F. Kimball (1917), former president of United Service Organizations and National Urban League Charles Bierer Wrightsman (1918), oil executive and art collector Armand Hammer (1919), philanthropist, chairman of Occidental Petroleum, namesake of Hammer Museum and Armand Hammer United World College of the American West George E. Jonas (1919), partner at Pellessier-Jonas-Rivet Manufacturing Co., philanthropist and founder of Camp Rising Sun S. Marshall Kempner (1919), investment banker, and brother-in-law of Peggy Guggenheim John S. Sinclair (1920), fourth president of the Federal Reserve Bank of Philadelphia, former president of The Conference Board Charles M.
=== Expansion === SHIELD Illinois was originally intended to be a facilitator, assisting laboratories in preparing to use the covidSHIELD assay and advising colleges, universities, and other organizations on how to collect specimens. SHIELD Illinois would also provide the technology needed to transmit orders to the lab and results back to the collecting agency. It was estimated that the program would have 50 testing locations and collect 1.5 million tests over a six-month period. Over time, SHIELD Illinois's role expanded beyond its original advisory function, and it became involved in the logistics of running both laboratories and collection sites. However, the estimated number of labs and locations remained the same. This changed in March 2021, when the University of Illinois System entered into an Intergovernmental Agreement with the Illinois Department of Public Health to offer testing to every school district, community college, and public university in Illinois, as well as community testing sites for the general public throughout the state. There are 853 school districts covering 3,977 with 1.9 million students in Illinois. As of October 2022, the company had performed over 6.5 million tests at over 1,700 sites in Illinois, including the governor's office, the state legislature, and the United States District Court for the Northern District of Illinois; engaged 12 CLIA or CAP-certified laboratories; and built a transportation network covering 80,000 square miles.
=== Codeine === Codeine was discovered in 1832 by Pierre Jean Robiquet. Robiquet was reviewing a method for morphine extraction, described by Scottish chemist William Gregory (1803–1858). Processing the residue left from Gregory's procedure, Robiquet isolated a crystalline substance from the other active components of opium. He wrote of his discovery: "Here is a new substance found in opium ... We know that morphine, which so far has been thought to be the only active principle of opium, does not account for all the effects and for a long time the physiologists are claiming that there is a gap that has to be filled." His discovery of the alkaloid led to the development of a generation of antitussive and antidiarrheal medicines based on codeine.
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.